StockData
Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp. (AVXL) shareholders

AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 28, 2026Score 6/30
$0.72−0.02 (-2.78%)

Close on Nov 18, 2026Market cap $66.69MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
39.9%
37M of 93M shares
Institutional holders
179
24 new, 32 sold out
Net institutional buying
-3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.6,671,0758.10%13G (passive) amendmentDec 31, 2023
Vanguard Capital Management4,663,4595.03%13G (passive)Jun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of AVXLValueChange% of portfolio
BlackRock, Inc.8,055,6288.69%$20.86M+446,0100.00%
Vanguard Capital Management LLC4,054,5894.37%$10.50M+190,6390.00%
Two Sigma Investments, LP3,046,5383.29%$7.89M−201,3500.01%
Geode Capital Management, LLC2,407,4732.60%$6.24M+219,1980.00%
State Street Corp1,922,7702.07%$4.98M−2,589,2580.00%
Federated Hermes, Inc.1,071,8091.16%$2.78M+539,5570.00%
Aqr Capital Management LLC963,0141.04%$2.49M+206,2220.00%
Vanguard Portfolio Management LLC948,6331.02%$2.46M+165,4850.00%
Summit Financial, LLC909,4300.98%$2.36M−31,0250.03%
Goldman Sachs Group Inc890,6340.96%$2.31M+86,1990.00%
Marshall Wace, Llp889,5230.96%$2.30M+470,0260.00%
Northern Trust Corp784,4940.85%$2.03M+59,3070.00%
Barclays PLC754,2260.81%$1.95M+215,9490.00%
Charles Schwab Investment Management Inc734,7950.79%$1.90M−21,7630.00%
Bank Of America Corp /De/654,2950.71%$1.69M−208,8550.00%
Vanguard Fiduciary Trust Co621,4510.67%$1.61M−25,7180.00%
UBS Group AG620,3740.67%$1.61M+50,4180.00%
Private Advisor Group, LLC504,0000.54%$1.31M+4,3000.01%
LPL Financial LLC406,1090.44%$1.05M−12,5310.00%
Stifel Financial Corp332,5970.36%$861.43K+95,7930.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202617937M39.9%24 / 6456 / 324M7M
Q1 202619040M43.1%38 / 7546 / 2912M5M
Q4 202518538M40.9%29 / 6055 / 278M2M
Q3 202518633M35.5%27 / 5749 / 173M2M
Q2 202517833M35.1%24 / 6934 / 253M2M
Q1 202518131M33.9%39 / 5943 / 255M3M
Q4 202416830M31.9%47 / 5039 / 225M2M
Q3 202414527M29.2%24 / 4729 / 1910M3M
Q2 202414127M29.0%21 / 4243 / 263M9M
Q1 202414733M35.2%17 / 5343 / 238M2M
Q4 202315326M28.5%27 / 5636 / 173M2M
Q3 202314325M27.0%13 / 5347 / 142M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

120 funds held AVXL in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of AVXLValue% of fundAs of
Vanguard Total Stock Market Index Fund2,925,4393.16%$7.58M0.00%Jun 30, 2026
iShares Russell 2000 ETF2,417,9822.61%$6.26M0.01%Jun 30, 2026
Federated Hermes MDT Small Cap Core Fund2,045,0982.21%$5.62M0.25%Jul 31, 2026
Vanguard Extended Market Index Fund1,041,5141.12%$2.70M0.00%Jun 30, 2026
Fidelity Small Cap Index Fund1,002,5751.08%$2.76M0.01%Jul 31, 2026
iShares Russell 2000 Value ETF737,4600.80%$1.91M0.01%Jun 30, 2026
iShares Biotechnology ETF631,7480.68%$1.64M0.02%Jun 30, 2026
Fidelity Extended Market Index Fund484,7080.52%$1.47M0.00%May 31, 2026
Vanguard Russell 2000 Index Fund450,2820.49%$1.36M0.01%May 31, 2026
Schwab U.S. Small-Cap ETF440,2090.47%$1.33M0.01%May 31, 2026
iShares Micro-Cap ETF310,0510.33%$803.03K0.05%Jun 30, 2026
Vanguard Health Care Index Fund266,1230.29%$806.35K0.00%May 31, 2026
Schwab Small-Cap Index Fund224,8670.24%$618.38K0.01%Jul 31, 2026
Master Small Cap Index Series186,6620.20%$483.45K0.01%Jun 30, 2026
Fidelity Total Market Index Fund175,9830.19%$533.23K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Terrie KellmeyerPresident and CEO, Director––Nov 6, 2026
Christopher U. MisslingPresident and CEO, Director1,510,1651.63%Jan 9, 2026
Sandra BoenischPFO & Treasurer67,9630.07%Sep 28, 2026
Axel PaegerDirector––Nov 6, 2026
Peter D.O. DonhauserDirector5,0000.01%Nov 6, 2026
Claus Vander VeldenDirector––Nov 6, 2026
Gautam PatelDirector––Oct 5, 2026
Adrian SenderowiczDirector––Oct 5, 2026
Steffen ThomasDirector55,0000.06%Jun 9, 2025
Athanasios SkarpelosDirector1,306,4581.41%Apr 2, 2025
Jiong MaDirector––Apr 2, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Christopher U. Missling
President and CEO, Director
Sep 11, 2025Tax withholding−145,048$9.58$1.39M1,510,165
Christopher U. Missling
President and CEO, Director
Sep 11, 2025Option exercise+187,500$5.04$945.00K1,655,213
Steffen Thomas
Director
Jun 5, 2025Option exercise+50,000$1.76$88.00K55,000
Steffen Thomas
Director
Jun 5, 2025Tax withholding−11,349$7.75$87.95K43,651
Christopher U. Missling
President and CEO, Director
Mar 24, 2025Option exercise+500,000$0.92$460.00K1,750,210
Christopher U. Missling
President and CEO, Director
Mar 24, 2025Tax withholding−282,497$9.63$2.72M1,467,713
Peter D.O. Donhauser
Director
Jun 14, 2024Buy+2,835$3.64$10.32K5,000
Steffen Thomas
Director
May 15, 2024Buy+5,000$4.52$22.60K5,000
Christopher U. Missling
President and CEO, Director
Mar 28, 2024Option exercise+73,380$1.32$96.86K1,323,590
Christopher U. Missling
President and CEO, Director
Mar 28, 2024Sale−73,380$5.11$374.97K1,250,210
Christopher U. Missling
President and CEO, Director
Jun 29, 2023Option exercise+232,000$1.60$371.20K1,250,210
Christopher U. Missling
President and CEO, Director
Jun 28, 2023Option exercise+268,000$1.60$428.80K1,286,210
Christopher U. Missling
President and CEO, Director
Jun 28, 2023Sale−268,000$7.98$2.14M1,018,210
Athanasios Skarpelos
Director
May 25, 2022Sale−50,000$9.06$453.00K1,306,458
Athanasios Skarpelos
Director
May 25, 2022Option exercise+50,000$0.92$46.00K1,356,458
Christopher U. Missling
President and CEO, Director
Jun 29, 2021Option exercise+51,620$1.32$68.14K1,069,830
Christopher U. Missling
President and CEO, Director
Jun 29, 2021Sale−51,620$26.00$1.34M1,018,210
Sandra Boenisch
PFO and Treasurer
Jun 29, 2021Option exercise+25,000$5.68$142.00K47,963
Sandra Boenisch
PFO and Treasurer
Jun 29, 2021Option exercise+106,696$3.28$349.96K154,659
Sandra Boenisch
PFO and Treasurer
Jun 29, 2021Option exercise+35,000$5.92$207.20K189,659
Sandra Boenisch
PFO and Treasurer
Jun 29, 2021Sale−166,696$26.53$4.42M22,963
Elliot Favus
Director
May 21, 2021Option exercise+1,500$4.90$7.35K92,000
Elliot Favus
Director
May 21, 2021Option exercise+50,000$2.96$148.00K145,000
Elliot Favus
Director
May 21, 2021Option exercise+1,500$6.11$9.17K95,000
Elliot Favus
Director
May 21, 2021Option exercise+1,500$5.66$8.49K93,500
Elliot Favus
Director
May 21, 2021Sale−145,000$11.70$1.70M0
Elliot Favus
Director
May 21, 2021Option exercise+1,500$5.57$8.36K90,500
Elliot Favus
Director
May 21, 2021Option exercise+1,500$5.64$8.46K89,000
Elliot Favus
Director
May 21, 2021Option exercise+50,000$0.92$46.00K87,500
Elliot Favus
Director
May 21, 2021Option exercise+37,500$1.20$45.00K37,500
Peter D.O. Donhauser
Director
May 17, 2021Buy+1,000$10.93$10.93K2,165
Elliot Favus
Director
Feb 24, 2021Option exercise+45,500$2.58$117.39K45,000
Elliot Favus
Director
Feb 24, 2021Option exercise+100,000$3.28$328.00K145,000
Elliot Favus
Director
Feb 24, 2021Sale−145,500$12.66$1.84M0
Peter D.O. Donhauser
Director
Feb 19, 2021Buy+165$12.97$2.14K1,165
Peter D.O. Donhauser
Director
Feb 19, 2021Buy+1,000$12.62$12.62K1,000
Christopher U. Missling
President and CEO, Director
Mar 7, 2018Buy+1,360$2.92$3.97K1,018,210
Christopher U. Missling
President and CEO, Director
Mar 6, 2018Buy+1,450$2.73$3.96K1,016,850
Christopher U. Missling
President and CEO, Director
Mar 5, 2018Buy+1,500$2.63$3.95K1,015,400
Christopher U. Missling
Director, President & CEO
Mar 2, 2018Buy+1,650$2.41$3.98K1,013,900
Christopher U. Missling
President and CEO, Director
Oct 25, 2017Buy+375$4.39$1.65K1,012,250
Christopher U. Missling
President and CEO, Director
Oct 24, 2017Buy+375$4.92$1.85K1,011,875
Christopher U. Missling
President and CEO, Director
Oct 19, 2017Buy+375$4.49$1.68K1,011,500
Christopher U. Missling
President and CEO, Director
Oct 17, 2017Buy+375$4.27$1.60K1,011,125
Christopher U. Missling
President and CEO, Director
Oct 13, 2017Buy+750$4.22$3.17K1,010,750
Christopher U. Missling
President and CEO, Director
Oct 5, 2017Buy+375$4.30$1.61K1,010,000
Christopher U. Missling
President and CEO, Director
Oct 2, 2017Buy+375$4.20$1.58K1,009,625
Christopher U. Missling
President and CEO, Director
Sep 28, 2017Buy+375$4.21$1.58K1,009,250
Christopher U. Missling
President and CEO, Director
Sep 26, 2017Buy+375$3.88$1.46K1,008,875
Christopher U. Missling
President and CEO, Director
Sep 20, 2017Buy+375$4.23$1.59K1,008,500
Christopher U. Missling
President and CEO, Director
Sep 18, 2017Buy+375$4.40$1.65K1,008,125
Christopher U. Missling
President and CEO, Director
Sep 14, 2017Buy+375$4.58$1.72K1,007,750
Christopher U. Missling
President and CEO, Director
Sep 11, 2017Buy+375$4.81$1.80K1,007,375
Christopher U. Missling
President and CEO, Director
Sep 7, 2017Buy+375$4.76$1.79K1,007,000
Christopher U. Missling
President and CEO, Director
Sep 5, 2017Buy+375$4.90$1.84K1,006,625
Christopher U. Missling
President and CEO, Director
Aug 31, 2017Buy+375$4.48$1.68K1,006,250
Christopher U. Missling
President and CEO, Director
Aug 28, 2017Buy+375$4.44$1.67K1,005,875
Christopher U. Missling
President and CEO, Director
Aug 24, 2017Buy+375$4.54$1.70K1,005,500
Christopher U. Missling
President and CEO, Director
Aug 21, 2017Buy+375$4.07$1.53K1,005,125
Christopher U. Missling
President and CEO, Director
Aug 18, 2017Buy+375$3.81$1.43K1,004,750

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
13.29%
12M shares short
Days to cover
10.1
At 1M shares a day
Change since last report
-5.0%
From 13M shares
Short volume, 20 days
54.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Anavex Life Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 38,689 shares on Sep 22, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Christopher U. Missling
Officer
Mar 28, 202473,380$371.30KMar 28, 2024Exercised Stock Options
Christopher U. Missling
Officer
Jun 28, 2023268,000$2.14MJun 28, 2023Stock Option Exercise

Congress trades

2 trades in Anavex Life Sciences reported by 1 member of the House

MemberTypeTradedAmountFiled
Christopher L. Jacobs
NY27
SoldDec 12, 2022$1K–15KJan 20, 2023
Christopher L. Jacobs
NY27
BoughtOct 12, 2022$1K–15KNov 16, 2022

See a number that looks wrong?